Evidence map›Paper›PMID 32653383›Full record

SynthesisRespiratory investigation2020

Trends in clinical features of novel coronavirus disease (COVID-19): A systematic review and meta-analysis of studies published from December 2019 to February 2020.

Toshie Manabe, Hiroyasu Akatsu, Kazuhiko Kotani, Koichiro Kudo

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Respiratory investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Epidemiologic and clinical characteristics of multisystem inflammatory syndrome in adults: a rapid review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021
    Article
  6. Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver.Journal of clinical and translational hepatology · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Toshie ManabeJichi Medical University, Center of Community Medicine, Tochigi, Japan. Electronic address: manabe@kklabo.gr.jp.
Hiroyasu AkatsuNagoya City University Graduate School of Medicine, Department of Community-based Medical Education, Aichi, Japan.
Kazuhiko KotaniJichi Medical University, Center of Community Medicine, Tochigi, Japan.
Koichiro KudoYurin Hospital, Tokyo, Japan; Waseda University, Regional and Inter-Regional Studies, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince novel coronavirus disease (COVID-19) emerged, various clinical features of COVID-19 have been reported.

methodsWe conducted a systematic review of published studies reporting the clinical features of COVID-19. Two investigators independently searched PubMed (December 2019-February 2020) for eligible articles. A meta-analysis was performed to measure the frequencies of clinical outcomes and symptoms of COVID-19. A stratified analysis was conducted according to the timeline of outbreak and exposure histories: Group I, most patients were exposed to the Hunan seafood wholesale market and lived in Wuhan, Hubei province; Group II, patients lived in Hubei province but were not directly exposed to the market; and Group III, patients lived outside Hubei.

resultsThirteen studies, all from China, were eligible. The estimated mortality rate among all studies was 2.12%, but that in Group I was 8.66%. The incidence of acute respiratory distress syndrome in Group I was 20.00%. Both fever and cough were major symptoms, and their frequencies were higher in Group I than in Groups II and III, while the frequency of diarrhea in Group I was lower than that in Group III. The estimated frequency of dyspnea in Group I was 37.18%, while those in Groups II and III were 16.95% and 7.03%, respectively.

conclusionsThe trends in the clinical features of COVID-19 changed from December 2019 to February 2020. During this observation period, as the infection continued to spread, the clinical conditions for majority of patients became less severe with the changes in the route of transmission.

Indexed as

Coronavirus InfectionsPandemicsPneumonia, ViralChinaCoughCOVID-19DiarrheaDyspneaHumansIncidenceRespiratory Distress SyndromeTime FactorsCOVID-19Exposure historySARS-CoV-2TimelineTransmission

Identifiers

PMID32653383
PMCPMC7321050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.